Consensus Biogen Inc. Boerse Muenchen

Stocks

IDP

US09062X1037

Pharmaceuticals

Real-time Boerse Muenchen 07:13:54 2026-10-08 EDT			5-day change	1st Jan Change
196.66 ^EUR	-0.47%		-1.28%	+32.16%

07:22am	RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating	MT
10-07	AI companies run virtual drug trials, aim to improve success of human studies	RE

24a972d53dc4ae44a5af1e5767c.-ihdfI5uxLJqWEILboZKSpB5gugyvxRPVjWRDKpRyqM.lnosS_QksPQGbxMmW8EHe9gazo562VV5JlPlaesmi83OTzJL5Dur3CxsMQ~eb3b07ded08f06873582686072253cae

Analysts' recommendations: Biogen Inc.

07:22am	RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating	MT
09-03	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
08-25	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
08-13	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
08-10	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
08-03	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
07-30	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
07-30	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT
07-30	Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating	MT
07-30	Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating	MT
07-30	BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating	MT
07-30	UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating	MT
07-30	RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating	MT
07-29	JPMorgan Lifts Biogen Price Target to $210 From $185	MT
07-29	Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating	MT
07-29	Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214	MT
07-28	Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating	MT
07-24	Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating	MT
07-21	BofA Securities Adjusts Biogen Price Target to $215 From $217	MT
07-21	Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating	MT
07-14	Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206	MT
07-13	Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+11.82%
	JOHNSON & JOHNSON					+8.2%
	ABBVIE INC.					+3.47%
	MERCK & CO., INC.					+9.45%
	ROCHE HOLDING AG					+4.35%
	NOVARTIS AG					+4.69%
	ASTRAZENECA PLC					+30.29%
	AMGEN INC.					-5.23%
	GILEAD SCIENCES, INC.					+8.46%
	Average					+8.39%
	Weighted average by Cap.					+8.80%